Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). (2020). SKIN The Journal of Cutaneous Medicine, 4(6), s84. https://doi.org/10.25251/skin.4.supp.84